Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - Additional Information (Detail)

v3.8.0.1
Commitments and Contingencies - Additional Information (Detail)
€ in Millions
 1 Months Ended 3 Months Ended
Aug. 11, 2016
Jul. 27, 2017
EUR (€)
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Sep. 30, 2017
USD ($)
Operating Leased Assets [Line Items]          
Loss Contingency, Accrual, Current     $ 1,800,000   $ 2,400,000
Loss Contingency Accrual, Provision     200,000 $ 6,000  
Legal Fees     $ 400,000 $ 500,000  
Business Combination, Contingent Consideration Arrangements, Description Fortress contends that no such payment is due because a condition of the EUR 2.5 million payment was the delivery of a Clinical Study Report that addressed the primary and secondary objectives of a Phase II trial, and Fortress contends that Dr. Falk Pharma failed to deliver such a Clinical Study Report. Dr. Falk Pharma disputes that it failed to deliver such a report and further disputes that the delivery of such a report is a condition of Fortress’s obligation to make the EUR 2.5 million payment. After the parties’ attempts to negotiate a settlement of the dispute were unsuccessful, Dr. Falk Pharma filed a lawsuit against Fortress in the above-referenced Court in Frankfurt, Germany to recover the EUR 2.5 million plus interest and attorneys’ fees, and Fortress was served with the English translation of the lawsuit on August 11, 2016. Fortress retained local counsel and, on December 14, 2016, filed an answer to the complaint, denying that it had any liability to Dr. Falk Pharma.        
Dr. Falk Pharma [Member]          
Operating Leased Assets [Line Items]          
Proceeds from Legal Settlements | €   € 2.5